Pharma Industry News
A collection of Pharma latest news, analysis and best practices from top business influencers and the world's most trustworthy sources.
Focus on quality, so that innovation efforts are not wasted: DCGI tells pharma industry
As the Indian drug regulator takes steps to align with the global regulatory system, the Indian pharmaceutical industry needs to undergo a cultural shift, take ownership and focus its efforts on quality, said Rajeev Raghuvanshi, the Drugs…
Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz, a First-in-Market Biosimilar to Simponi (golimumab)
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz Pharma”), a UK headquartered global…
US pharma ramps up attack on Australia's 'discriminatory' drug pricing
The US pharmaceutical industry is increasing pressure on Donald Trump to take action against the Pharmaceutical Benefits Scheme, which it says makes Australia one of the most difficult countries in the world to get new medicines approved and…
Innocan Pharma announces promising results of LPT-CBD administered to Gottingen Minipigs, a well-known drug toxicology model
HERZLIYA, Israel and CALGARY, AB, Nov. 20, 2025 /CNW/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ('Innocan' or the 'Company'), a pioneer in the pharmaceutical and biotechnology industries, proudly announces the publication…
LSL PHARMA GROUP REPORTS FOURTH CONSECUTIVE RECORD QUARTERLY REVENUES AND Q3 2025 FINANCIAL RESULTS
9-months YTD-25 consolidated revenues up 73% over prior year, at $21.4 million 9-months YTD-25 Adjusted EBITDA up 90% over the prior year, at $3.1 million Secured Health Canada approval for 6 eye-drops to be launched in 2026 Expanded the CMO…
BridgeBio Pharma (NASDAQ:BBIO) Director Sells $3,612,950.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrew Lo sold 55,000 shares of the company's stock in a transaction on Tuesday, November 18th. The shares were sold at an average price of $65.69, for a total value of $3,612,950.00.
How AI Stands To Shift HCP Marketing In 2026 And Beyond
Kamya Elawadhi is Chief Client Officer at Doceree. In the pharmaceutical space, AI isn't just impacting the clinical trial process. It's also impacting HCP marketing—how pharmaceutical products reach healthcare professionals. We're already…
BridgeBio Pharma (NASDAQ:BBIO) Director Sells $666,500.00 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Randal Scott sold 10,000 shares of the business's stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $66.65, for a total transaction of…
Terrance Coyne Sells 69,594 Shares of Royalty Pharma (NASDAQ:RPRX) Stock
Royalty Pharma PLC (NASDAQ:RPRX - Get Free Report) CFO Terrance Coyne sold 69,594 shares of the company's stock in a transaction dated Monday, November 17th. The stock was sold at an average price of $39.30, for a total value of $2,735,044.20.
Urogen Pharma (NASDAQ:URGN) Shares Up 7.3% - Still a Buy?
Urogen Pharma (NASDAQ:URGN - Get Free Report) rose 7.3% on Wednesday. The stock traded as high as $25.07 and last traded at $25.27. Approximately 619,552 shares were traded during mid-day trading, a decline of 57% from the average daily volume of…
Road clear for Swiss self-driving car project
Truth or tale: Could conscription solve military personnel shortages? Read more: Truth or tale: Could conscription solve military personnel shortages? Rubble and drones: in the no-go zone between Lebanon and Israel Read more: Rubble and drones: in…
TD Cowen Downgrades Royalty Pharma (NASDAQ:RPRX) to Hold
Royalty Pharma (NASDAQ:RPRX - Get Free Report) was downgraded by TD Cowen from a 'strong-buy' rating to a 'hold' rating in a research note issued on Monday, Zacks.com reports. How Royalty Pharma Prints Cash Without Biotech's Biggest Risks A number…
Insider Selling: BridgeBio Pharma (NASDAQ:BBIO) Director Sells 40,599 Shares of Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) Director Andrew Lo sold 40,599 shares of BridgeBio Pharma stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $66.67, for a total value of…
BridgeBio Pharma (NASDAQ:BBIO) CFO Sells $1,125,433.64 in Stock
BridgeBio Pharma, Inc. (NASDAQ:BBIO - Get Free Report) CFO Thomas Trimarchi sold 16,934 shares of the stock in a transaction dated Monday, November 17th. The shares were sold at an average price of $66.46, for a total transaction of $1,125,433.64.
BridgeBio Pharma, Inc. $BBIO Shares Sold by KBC Group NV
KBC Group NV lowered its position in shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO - Free Report) by 98.0% in the second quarter, according to its most recent 13F filing with the SEC. The firm owned 4,195 shares of the company's stock after selling…
Receive a Daily briefing on Pharma Industry News
Get Started